Aaron Gal

Allergan plc (NYSE: AGN) shares popped 5.6 percent Thursday on news of a possible stake by Carl Icahn. Attention from the activist investor would heighten the pressure for a strategic shift that's already being applied by Appaloosa and Senator Investment Group. The Rating Bernstein...

Celgene Corporation (NASDAQ: CELG) is down about 35 percent year-over-year, and as management resists challenges to critical Revlimid patents, analysts are at odds about where the stock could head from here. The Ratings Bernstein analyst Aaron Gal upgraded Celgene from Market-Perform to...

Following a 14-percent pullback in shares of Shire PLC (ADR) (NASDAQ: SHPG) since May 26, Bernstein said it expects a rebound, although expressed skepticism regarding a sustained rally. Analyst Aaron Gal is of the view the hemophilia market is likely to come under long-term pressure. While data...

Updating the M&A scenario in the chemicals space, Bernstein said in a note on Monday that there are currently six M&A live deals in its covered chemicals space, now that the PPG Industries, Inc (NYSE: PPG)–Akzo Nobel N.V. (ADR) (OTC: AKZOY) deal has been called off. Analysts Jeremy...

Biotech investors may have noticed that the first quarter of the year is a bit sluggish for drug sales. They aren’t imagining things, according to Bernstein analyst Aaron Gal. Bernstein analyzed a group of about 40 drugs and found that Q1 sales declined by about 7 percent compared to Q4 sales...

Offering its insight into the formulary coverage of multiple sclerosis drugs for 2017, Bernstein said in a note released on Thursday it sees stabilization of formulary coverage after a year of tightening in 2016. Treatment Options MS is a neurodegenerative disease affecting young adults,...

Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD), a condition in which fat builds up in a person's liver. As noted by the National Institute of Diabetes and Digestive and Kidney Diseases, there are no approved medicines to treat NAFLD and NASH. In a...

Bernstein has initiated coverage of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) with an Outperform rating and $400 price target, citing a "good entry point for one of stronger growers in biotech." "Regeneron is a growth-phase biopharma with one large successful first product (Eylea) and two...

Biogen Inc (NASDAQ: BIIB) has an aging MS franchise, but a solid biosimilar pipeline is sure to offset the loss of Tecfidera, Avonex and Tysabri. Bernstein's Aaron Gal initiated Biogen at outperform and set a price target of $282. The multiple sclerosis franchise has a five-year runway as...

Bernstein's Aaron Gal initiated Amgen, Inc. (NASDAQ: AMGN) at Market Perform and set a price target of $161. The company will have a hard time offsetting "stiff biosimilar headwinds," Gal noted. Amgen has a very old drug portfolio with G-CSFs, ESAs and Enbrel accounting for over 100 percent of its...

Allergan plc Ordinary Shares (NYSE: AGN), Alcon, Shire PLC (ADR) (NASDAQ: SHPG) and, to a lesser extent, Bausch & Lomb are the active buyers of ophthalmology products/companies, according to a note from Bernstein citing venture capitalist Emmett Cunningham. Of note, Alcon is a subsidiary of...

Shares of Theravance Inc (NASDAQ: THRX) fell more than 12 percent Wednesday morning after the company's commercial partner, GlaxoSmithKline plc (ADR) (NYSE: GSK), disclosed topline results from SUMMIT. Theravance's trial attempted to prove survival benefits for Breo in COPD patients and failed to...